To address the poor prognosis of mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia (iALL), we generated a panel of cell lines from primary patient samples and investigated cytotoxic responses to contemporary and novel Food and Drug Administration-approved chemotherapeutics. To characterize representation of primary disease within cell lines, molecular features were compared using RNA-sequencing and cytogenetics. High-throughput screening revealed variable efficacy of currently used drugs, however identified consistent efficacy of three novel drug classes: proteasome inhibitors, histone deacetylase inhibitors and cyclindependent kinase inhibitors. Gene expression of drug targets was highly reproducible comparing iALL cell lines to matched primary specimens. Histone deacetylase inhibitors, including romidepsin (ROM), enhanced the activity of a key component of iALL therapy, cytarabine (ARAC) in vitro and combined administration of ROM and ARAC to xenografted mice further reduced leukemia burden. Molecular studies showed that ROM reduces expression of cytidine deaminase, an enzyme involved in ARAC deactivation, and enhances the DNA damage-response to ARAC. In conclusion, we present a valuable resource for drug discovery, including the first systematic analysis of transcriptome reproducibility in vitro, and have identified ROM as a promising therapeutic for MLL-rearranged iALL.
INTRODUCTION
Infants with acute lymphoblastic leukemia (iALL) comprise a highrisk group with inferior outcome compared with older children. 1 Adverse risk factors include presence of a mixed lineage leukemia (MLL/KMT2A) gene rearrangement (MLL-r), hyperleukocytosis at presentation, age o 90 days at diagnosis and poor response to initial prednisone therapy. 2, 3 Contemporary treatment uses doseintensive chemotherapy combinations. However, 5-year event-free survival remains o40% for MLL-r iALL, 4, 5 highlighting the need to identify novel drugs to improve outcome.
Genomic profiling and high-throughput compound screening of patient-derived cell lines have identified personalized treatments in breast 6 and lung 7 cancer and catalogued predictive biomarkers of drug-responses across large collections of human cancer cell lines. [8] [9] [10] However, in vitro cancer drug screening is limited by the absence of cell line characterization in relation to the primary disease. For example, over 40 leukemia cell lines have been reported as MLL-r, including monocytic (for example, MV4-11, MOLM-13, THP-1), immature T-ALL (for example, Karpas 45, SUP-T13) and B-cell precursor ALL (for example, SEM, RS4;11); but there are few reports verifying the molecular representation of cell lines derived from rare clinical sub-types, such as iALL. 11 We previously demonstrated variable cytotoxic response between two iALL cell lines to contemporary chemotherapeutics 12 highlighting the need to test multiple patient-derived lines. Thus, a panel of genetically characterized cell lines derived from iALL patients with defined clinical features is a crucial resource for drug discovery. To address these requirements, we established cell lines from infants with high-risk MLL-r iALL, performed a comprehensive molecular comparison with primary specimens and assessed drug sensitivity in vitro. We identified several novel drug classes with consistent efficacy, including histone deacetylase inhibitors (HDACi), proteasome inhibitors and cyclin-dependent kinase inhibitors. Pre-clinical assessment of romidepsin (ROM), a US Food and Drug Administration (FDA)-approved HDACi, revealed synergy with cytarabine (ARAC) in vitro and further reduction of leukemic burden in vivo. Thus, we describe a novel resource for drug discovery and identify promising new therapies for iALL. 47 , XX,der(4)t(4;11)(q21;q23), add(4) (p16),+6, del(7)(p14),add(8)(q24.3),der(9) inv(9)(p11q12) del(9)(p24), der (11) [15] .ish t(2;11) (3`MLL+;5`MLL+) [10] .nuc ish(MLLx2) (5`MLLsep3`MLLx1) [198/200] ; der(11), der(2) and der (13) in complex rearrangement (FISH).
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ND 46,XX,t(4;11)(q21;q23),der (19) 19 Analyses were performed using R (v3.1.2). Gene ontology enrichment analysis was performed using DAVID. 20 MLL-fusion split-reads were identified with FusionFinder 21 using default settings. Split-reads containing identical strings of MLL-and candidate fusion gene sequences were extracted using 'grep', searching for chimeric sequences with 15 nucleotides flanking the fusion.
In vitro drug sensitivity
In vitro cell viability assays were performed using a modified alamarBlue assay with cells in logarithmic growth. After 72 h drug exposure, alamarBlue reagent was added and cell viability determined by fluorescence intensity (excitation 555 nm, emission 585 nm). Synergy experiments focused on drugs that form a key component of iALL therapy, ARAC and dexamethasone, combined with novel drugs identified from our screen, bortezomib and ROM, with biological replicates (n = 2). Experimental conditions are provided in the Supplementary Information.
Antibodies, immunoblotting and fluorescence staining
The antibodies used were as follows: α-CD19-FITC (Cat 555412, BD Biosciences, Franklin Lakes, NJ, USA), goat α-rabbit-APC (Cat 3846 Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal α-cytidine deaminase (CDA) (SAB 1300717; Sigma, St Louis, MO, USA), rabbit polyclonal α-deoxycytidine kinase (DCK) (ab151966; Abcam, Cambridge, MA) and α-Actin (A1978-200UL, Sigma). Flow cytometry was performed with the BD LSRII (BD Biosciences). Leukemia burden was quantified by harvesting mouse organs and subjecting cell suspensions to flow cytometry with α-human CD19-FITC antibody or no stain. Data analysis was performed using FlowJo software v10.0.5 (Tree Star, Ashland, OR, USA). For dual PI-γ-H2AX staining, cells were fixed and permeabilised with 1% formaldehyde and 0.1% triton-X. Cells were incubated with 2 µl of primary α-Phospo-Histone γ-H2A.X rabbit mAb (Cat 9718, Cell Signaling Technology, Danvers, MA, USA) for 20 min; and with 1 ul of secondary goat α-rabbit-APC for 20 min. PI was added (final concentration 100 µg/m) before flow cytometric analysis. Cell lysates were prepared for immunoblot using Evans buffer and proteins subject to SDS-PAGE using the NuPage 4-12% Bis-Tris Gel (NP0321, Life Technologies, Carlsbad, CA, USA). Membranes were scanned using the ChemiDoc MP Imaging System (Bio-Rad, Philadelphia, PA, USA). 
Drug-response in vivo

Statistical analysis
Dose-response curves were used to calculate IC 50. The area above the dose-response curve (activity area) was determined as described. 8 Bar graphs, dot-plots and statistics were generated using GraphPad Prism (v6.0c) with two-sample t-tests or one-way analysis of variance and Tukey's multiple comparison tests. Synergy was scored using Chalice software (Horizon CombinatoRx Inc., Cambridge, MA, USA), applying the Bliss-independence model. 23 Bliss-excess synergy scores were summed across matrices to rank combination effects. Scatterplots and heatmaps were drawn with gplots and ggplot2 and hierarchical clustering and correlation analysis were performed in R (v3.1.2).
RESULTS
Establishment and characterization of iALL cell lines
Cell lines were generated from four infant ALL patients diagnosed at o90 days of age and one relapse patient, who was initially diagnosed at 339 days (Table 1) . Fluorescence in situ hybridization (FISH) identified the MLL-rearrangement in each patient specimen and matched cell line. G-banded chromosomal analysis revealed sideline clones in cell lines, with structural and numerical changes undetected in patient specimens. 12, 13, 24 DNA fingerprinting revealed identical short tandem repeat profiles for each patient cell line pair except for cell line PER-703A. It lacked a single marker at the TH01 locus on chromosome 11 (Supplementary Table S1 ), which corresponded with loss-of-heterozygosity of chromosome 11 in this cell line. These results confirmed 100% concordance of DNA markers in cell lines and patient specimens. Immunophenotypic analysis of cell lines revealed a phenotype expressing B-lymphoid (CD19 or CD24) and myeloid (CD33) markers (Table 2 ). Cell lines PER-784A and PER-826A were also positive for CD7.
Detection of MLL-fusion transcripts Concordant MLL-fusion partners (Supplementary Table S2) were found for each patient cell line pair. Expression of the reciprocal fusion transcript was detected in two patient samples (P810 (EPS15-MLL) and P399 (AFF1-MLL)) and in each of their matched cell lines. Alternative splice junctions fusing variant MLL exons with partner genes were observed in three patients (P287, P377 and P399), with the same splice variants identified in matched cell lines indicating concordance of MLL-fusion transcripts in iALL cell lines. 
Comparative transcriptome analysis The RNA-seq data set comprised 614 million paired end reads, with a median of 47 million read pairs per sample. There were 15 612 expressed genes, defined with a detection cutoff of 75+ reads in two or more of the 13 samples analyzed (five primary and eight cell lines). Using IDRo0.05, concordant expression was observed in up to 81% of genes (range: 65-81% total transcripts; n = 10208-12655; Figure 1a , Supplementary Figure S1A ). By intersecting concordantly expressed genes in each cell line and primary sample pairing, we found 8677 genes (56% of all detectable transcripts), representing the iALL transcriptome with reproducible expression across primary samples and multiple cell cultures. Analysis of genesets characteristic of hematopoietic progenitors 25 revealed similar expression distributions in primary specimens and corresponding cell lines (Supplementary Table S3 ; Supplementary Figure S1B ).
Discordant expression was defined as genes detected in paired samples at levels less than 0.0625 and greater than two counts per million (cpm), revealing 203 genes (1.3% total transcripts) expressed at higher levels in cell lines relative to the matched patient specimen, including 41 genes identified in two or more unrelated cell lines (Supplementary Figure S1C ; Supplementary Table S4) . There were 729 genes (4.7% total transcripts) expressed at lower levels in cell lines relative to patient specimens (Supplementary Figure S1D ; Supplementary Table S5), including 233 genes in two or more unrelated cell lines. Ontology analysis of genes at higher levels in cell lines (152 genes mapped to Gene Ontology terms; Supplementary Table S4) suggests an over-representation of inflammatory response (15-fold enrichment; Benjamini-Hochberg (BH) adjusted P = 0.37; for example, IL2RA, CD276) and cell signalling (3.1-fold enrichment; BH adjusted P = 0.18; for example, SIGLEC6, PMP22) genes. In contrast, genes at lower levels in cell lines (569 genes mapped to Gene Ontology terms; Supplementary  Table S5 ) are over-represented in immune response (3.0-fold enrichment; BH adjusted P = 1.18 × 10 − 10 ; for example, CR1, CR2), antigen-binding (7.9-fold enrichment; BH adjusted P = 3.49 10 À 5 ; for example, Fc-receptors, immunoglobulins and T-cell receptors) and hematopoietic cell lineage (3.9-fold enrichment; BH adjusted P = 0.04; for example, KIT, CD14, IL1R2) genes.
Gene expression stratified by Ensembl gene-type annotations (n = 15 250) identified 12 130 protein-coding genes (80% of annotated transcripts). Among non-coding (nc) RNA bio-types, processed pseudogenes (n = 922) were the most numerous followed by anti-sense-RNA (n = 915) and long intergenic RNA (n = 556). The set of ncRNAs were consolidated to compare expression of the major RNA bio-types including protein-coding genes, pseudogenes (n = 1261) and other ncRNA genes (n = 1855) (Supplementary Table S6 ). We found lower expression of ncRNA genes compared with protein-coding genes in primary and matched cell lines, with a similar distribution of the ncRNA bio-types (Figure 1b) , consistent with data from normal human tissues. 26 When cataloguing conserved in vitro expression across all of the eight cell lines (8677 annotated genes with IDR o 0.05; Supplementary Table S6) , we identified 7666 protein-coding transcripts, 535 pseudogenes (including 419 processed pseudogenes) and 353 ncRNA (including 190 anti-sense-RNA and 86 long intergenic RNA bio-types). These results reveal similarities in expression of RNA bio-types in primary samples and iALL cell lines.
Effective drug classes comprise inhibitors of proteasome, cyclindependent kinase and histone deacetylase Our screening strategy focused on identifying novel FDA-approved agents that may also enhance chemotherapeutics. A summary of the initial and secondary screens in Supplementary Figure S2A includes drug information and experimental conditions. The initial screen of 101 FDA-approved cancer drugs (Supplementary  Table S7 ) was performed at three doses, revealing heterogeneity Figure S2B) . However, we identified proteasome inhibitors and HDACi drug classes that were consistently effective at nanomolar concentrations. We next assessed IC 50 concentrations on a panel of drugs, including proteasome inhibitors, HDACis, conventional chemotherapeutics and their analogues and rationally chosen targeted inhibitors (Supplementary Figure S2C) . These data confirmed variable responses to chemotherapeutics, including dexamethasone, prednisone, ARAC, methotrexate, 6-mercaptopurine, L-asparaginase, thioguanine, etoposide, daunorubicin and 4-hydroxycyclophosphamide. Clofarabine and gemcitabine demonstrated higher efficacy compared with conventional agents within the same drug class (that is, antimetabolites and pyrimidines) used to treat iALL. In accordance with large-scale drug screens, 8 we found consistent efficacy at nanomolar range of vincristine (Figure 2) .
Consistent low IC 50 concentration within nanomolar range, was confirmed for several drugs belonging to proteasome inhibitor and HDACi drug classes. These included three of four proteasome inhibitors, bortezomib (IC 50 range: 4-10 nM), carfilzomib (3-20 nM) and delanzomib (8-10 nM), with higher IC 50 doses for MG-132 (0.67-1.25 μM). Two HDACis had consistent nanomolar IC 50 doses, panobinostat (4-50 nM) and ROM (3-10 nM), with higher IC 50 doses for vorinostat (0.7-10 μM) and belinostat (0.14-1.1 μM). We also observed nanomolar IC 50 doses for three of five cyclin-dependent kinase inhibitors. Dinaciclib was the most potent (8-12 nM), followed by flavopiridol, (200-350 nM) and SN-032, (213-295 nM). In contrast, PD0332991 was cytotoxic in one cell line, whereas roscovitine was not cytotoxic.
We also identified drugs showing efficacy within micromolar dose range. These included a BCL2-inhibitor, obatoclax (IC 50 range: 0.2-3.8 μM), and bromodomain and extra-terminal domain family inhibitors, GSK1210151 (0.16-2.4 μM), GSK525762 (0.19-2.1 μM) and JQ1 (0.15-1.35 μM). The JMJD3/UTX H3K27-demethylase inhibitor, GSK-J4, was cytotoxic in four cell lines (1.6-2.3 μM). The EZH2-inhibitor, GSK-343, was not cytotoxic. Drugs targeting receptor tyrosine kinases were generally not cytotoxic, except for lestaurtinib (0.02-1.9 μM) and crizotinib (1.5-3.3 μM).
Conserved in vitro expression of drug target genes We used RNA-seq data to investigate the expression of drug targets in eight cell lines (Supplementary Table S8 Table S8) . Thus, we found broadly concordant in vitro RNA expression of molecules targeted by HDACis, proteasome inhibitors, cyclin-dependent kinase inhibitors and histone H3K27 methylase/demethylase inhibitors and variable expression of receptor tyrosine kinase-encoding genes.
Patient cell line-specific drug interactions Bortezomib and ROM were the novel drugs chosen for further assessment, owing to their consistent effect in our screen, availability in a formulation suitable for infants and as they have translational potential given they are FDA-approved and undergoing clinical assessment for hematological malignancies. ROM consistently and significantly enhanced the effect of ARAC in five of six cell lines (Figure 3a) , reducing the concentration of ARAC required for 50% growth inhibition by 5.9-fold (PER-485A), 4.0-fold (PER-785A), 3.8-fold (PER-826A) 3.1-fold (PER-703A) and 1.5-fold (PER-490A). ROM enhanced dexamethasone efficacy in PER-826A cell line by 1.1-fold and adversely affected dexamethasone cytotoxicity in PER-485A such that 50% growth inhibition was not achieved (Figure 3b) . The effects of bortezomib on ARAC and dexamethasone efficacy were variable. Bortezomib enhanced ARAC efficacy in PER-785A (5 nM; 5.9-fold IC 50 decrease), PER-703A (2 nM: 3.6-fold IC 50 decrease; 5 nM: 9.7-fold IC 50 decrease) and PER-826A (2 nM; 7.5-fold IC 50 decrease). In contrast, bortezomib reduced ARAC efficacy in PER-784A (2 nM; 3.7-fold IC 50 increase) and had no significant effect on ARAC efficacy in PER-490A or PER-485A (Figure 3a) . Bortezomib enhanced the efficacy of dexamethasone in PER-784A (2 nM: 1.4-fold IC 50 decrease) and in PER-785A (activity area shift from 1.5 (dexamethasone only) to 4.9 (dexamethasone with 5 nM bortezomib)) (Supplementary Figure S7) ; however, this difference was not captured by IC 50 change because cell death did not reach 50%. Bortezomib adversely affected the efficacy of dexamethasone in PER-485A such that 50% growth inhibition was not achieved (Figure 3b ). These results demonstrate consistent enhancement of ARAC efficacy by ROM with variable effects for other drug combinations. Our results confirm the inversecorrelation between IC 50 and activity area across all cell lines, with r = − 0.924 (Supplementary Figure S7A-C) .
HDAC-inhibitors synergize with ARAC in MLL-r iALL Combination drug testing in matrix format confirmed that the ARAC-ROM combination provided the strongest synergy in both PER-485A and PER-490A cell lines (Figure 3c Figure S8A-D) . In contrast, antagonism was observed with ROM-dexamethasone at several doses in both cell lines (Supplementary Figure S8E and F) . The borte zomib-dexamethasone combination, exceeded additive effects in PER-485A, but was antagonistic at higher bortezomib doses (Supplementary Figure S8G-H) .
Synergy testing was extended using four different HDACi drugs in an independent MLL-r iALL cell line (PER-826A). We confirmed synergistic interactions at all ARAC-ROM doses tested and also for ARAC-panobinostat, ARAC-mocetinostat and ARAC-LAQ824 combinations with varying magnitudes (Figure 3d ). In addition, we examined ARAC-ROM interaction in two pediatric ALL cell lines, of Pre-B and T-cell origin, lacking MLL-r and found additive effects in Pre-B-ALL cells (PER-278 with 1 nM ROM; 1.4-fold ARAC IC 50 decrease) and antagonistic effects in T-ALL cells (PER-117 with 1 nM ROM; 2.6-fold ARAC IC 50 increase). Thus, we found ROM enhances ARAC killing in five of six MLL-r iALL cell lines; three additional HDACi drugs capable of enhancing ARAC cytotoxicity; and ROM reduces ARAC efficacy in a germline-MLL T-ALL cell line and enhances ARAC efficacy in a germline-MLL Pre-B-ALL cell line.
ROM modulates cytidine-metabolizing enzymes and ARAC-induced DNA damage-response Next, we examined the expression of genes and pathways that could mediate the observed ARAC-HDACi combination drug effects (Supplementary Table S7 ) at steady state, and in perturbation experiments. HDAC-1/-2 repressor complex subunits ( Figure 4a) were analyzed, as these are potential targets of ROM, panobinostat and mocetinostat. 28 We detected 22 HDAC-repressor subunits, 29 at a cutoff of 0.0625 cpm. These include seven NuRD subunits, six CoREST subunits, seven SIN3 subunits and two core enzymes (HDAC-1/-2) with highly conserved in vitro expression (175/176 reproducible observations; Figure 4b ; Supplementary Table S7 ). In addition, we examined genes within the 'cytidine analogue pathway' involved in ARAC metabolism 30 Table S7) . We subjected the data to cluster analysis focusing on genes within the 'cytidine analogue pathway', which revealed separation of cell lines according to ARAC sensitivity (Supplementary Figure S9) ARAC, whereas CDA showed lower expression in the most sensitive cell lines, consistent with reports that ARAC cytotoxicity is limited by lower DCK activity and higher CDA activity. 31, 32 We hypothesized that ARAC-ROM synergy could be mediated by expression of cytidine-metabolizing enzymes and/or alterations to DNA damage-response pathways. We first monitored global histone changes (H3K27-acetylation and H3K79-dimethylation) with time-course experiments and found increases in H3K27-acetylation and H3K79-dimethylation detected at 6 h ROM exposure in iALL cells (data not shown). We next examined kinetics of DCK and CDA, key proteins in the cytidine metabolism pathway in response to ROM. CDA expression was reduced after 2 h incubation with ROM and decreased further at 4, 6 and 8 h (Figures 5a and b; n = 2) . In contrast, we did not detect reproducible changes in DCK expression (n = 3). As ARAC induces DNA damage during S-phase 33, 34 we tested whether ROM exposure modulates this response as measured by γ-H2AX and PI (DNA-content) staining in two cell lines with 16-fold differing ARAC-sensitivities. PER-826A (ARAC IC 50 = 1.79 μM) cells were treated with 5 μM ARAC, and PER-785A (IC 50 = 0.11 μM) were treated with 1 μM ARAC to measure DNA damage after 24 h. Single-agent ROM showed no significant effect on γ-H2AX levels ( Figure 5c ; ROM vs saline P40.05). In contrast, ARAC treatment significantly increased γ-H2AX in all phases of the cell cycle (ARAC vs saline Po0.0001). Co-dosing with ARAC-ROM induced significant γ-H2AX accumulation in S-phase compared with ARAC in both cell lines (PER-785A Po0.01, PER-826A Po0.01) and enhanced γ-H2AX across the cell cycle in PER-826A (G0-G1 Po0.001, G2-M Po0.05). Overall, these results reveal highly conserved in vitro expression of genes that could mediate ARAC-ROM interactions, and suggest ROM modulates the expression of cytidine-processing enzymes and enhances the DNA damage-response to ARAC.
ROM and ARAC activity in iALL xenografts PER-785A and PER-826A were injected into NOD/SCID mice and consistent engraftment in bone marrow was observed for PER-785A on day 11 and for PER-826A on day 18. Single-agent activity was assessed for ROM and bortezomib, but did not achieve extension of event-free survival when administered as single drug 5 days after mice were injected with PER-785A or PER-826A (data not shown). Hence, further examination of in vivo activity of the ARAC-ROM combination was prioritized owing to consistent enhancement of ARAC by ROM in vitro (5/6 cell lines; Figure 3a ) and the magnitude of synergy scores (Figure 3c ). For combination drug testing, mice were randomized on day 11 for PER-785A xenografts and on day 18 for PER-826A xenografts and drug treatments initiated with ROM, ARAC, ROM and ARAC or saline for 3 weeks (Figure 6a ; Material and Methods). Four days following the last drug injection leukemia burden was measured in bone marrow, spleen and blood. Leukemia infiltration in saline-treated animals shows the highest levels in bone marrow, followed by spleen and peripheral blood in both xenografts (Figure 6b) , with comparison between the two models revealing distinct features.
Separate experiments were performed with animals given ROM 6 h ('Schedule 1') or 18 h ('Schedule 2') before ARAC (Figures 6c  and d ). Following treatment with ARAC alone, mice xenografted with PER-785A showed a mean reduction of leukemic cells in bone marrow of 66% (Po0.0001; n = 5) with Schedule 1 and 58% (Po0.0001; n = 5) with Schedule 2 (Figure 6c ). Single-agent activity of ROM was observed with Schedule 1 in PER-785A xenografted mice with a mean reduction of leukemic cells of 16% (Po0.05; n = 5). Addition of ROM prior to ARAC in PER-785A xenografts resulted in a mean reduction of leukemic cells of 73% (Po0.0001; n = 5) with Schedule 1 and 67% (Po0.0001; n = 5) with Schedule 2 (Figure 6c) .
In PER-826A xenografts, single-agent ROM or ARAC did not reduce leukemia burden significantly in either experiment. However, when ROM was administered 6 h before ARAC (Schedule 1) the combined treatment reduced leukemia burden by 25% (95% C.I. 13-36%; were determined by normalizing to either DMSO controls (for dexamethasone or ARAC only treatment groups) or treatment with ROM or bortezomib only (for co-treated drug groups). Graphs display means of IC 50 , error bars represent 95% confidence intervals and P-values calculated by two-sample t-test (*P o 0.05, **P o 0.01, ***P o 0.001). Drug combinations were evaluated in three replicate experiments; single-agent dexamethasone and ARAC IC 50 were evaluated in six (PER-485A, PER-490A, PER-784A, PER-826A and PER-785A) or nine (PER-703A) replicates. Drug combination effects were not determined (ND) for bortezomib doses causing excessive cell death. (c) PER-485A or PER-490A cells were treated with increasing doses of ARAC or dexamethasone combined with ROM or bortezomib, at a fixed ratio with 1.2-fold incremental differences in drug concentrations. Cell viability was measured by alamarBlue at 72 h and synergy calculated by excess over Bliss. Bar graph displaying the sum of Bliss-excess scores (Bliss Volume) for each drug combination in cell lines PER-485A (green) and PER-490A (yellow). (d) PER-826A cells were treated with ARAC combined with HDACi drugs (ROM, panobinostat, mocetinostat and LAQ824) and synergy determined as described for (c).
Po0.0001; n = 5) compared with saline, by 15% (3.5-26%; Po0.01) compared with ROM-only and by 13% (1.6-25%; P o0.05) compared with ARAC only (Figure 6d ). Treatment with ROM 18 h before ARAC (Schedule 2) did not show significant differences compared with saline, or single-agent treated groups in PER-826A xenografts (Figure 6d right panel) . Therefore, PER-826A xenografts showed a poor response to ARAC, which could be enhanced by ROM.
DISCUSSION
Novel cancer drugs frequently fail to demonstrate the expected benefits when administered to patients, hence the need to review and improve pre-clinical drug screening. 35 Contributing factors include limitations of models used for cancer drug discovery, such as their representation of human disease. 36 A major criticism of cancer cell lines is that they do not fully represent the primary tumor. 37 Although the paradigm of molecular divergence in vitro is accepted, there are few reports comparing genomic profiles of primary specimens and derived cell lines. This is in contrast to patient-derived xenografts, for which several reports have investigated genomic changes following engraftment. 38, 39 In this study we focused on MLL-r iALL because of the urgent need for novel therapeutic approaches to improve outcome. We document the genetic and transcriptional landscape of a panel of cell lines and defined over 8000 genes expressed at reproducible levels across eight pairs of cell line/primary samples. This gene set comprised almost 7500 coding and hundreds of non-coding genes (pseudogenes and long non-coding RNAs) and is likely to include essential genes for iALL viability. Importantly, virtually all drug targets from our chemical screen were reproducibly expressed in the iALL cell lines when compared with matched primary specimens. These include targets of HDACis, proteasome inhibitors and cyclin-dependent kinase inhibitors. We also found evidence for multiple MLL-fusion isoforms in three cell lines present in matched primary samples. The MLL-fusion isoforms were due to alternative 5' MLL exon junctions, fused to an invariant 3' partner gene exon suggesting splicing heterogeneity in primary samples and iALL cell lines. Furthermore, we observe conserved in vitro expression of the major RNA bio-types. Altogether, these data support the utility of this panel of iALL cell lines for modelling molecular responses to chemical hits from our screen. 30 were detected including five membrane-bound transporters, 10 cytosolic processing enzymes and 11 genes whose expression levels correlate with ARAC sensitivity. (d) Scatterplots as for (b) with points coloured to show genes whose expression correlates with ARAC cytotoxicity (white), genes involved in ARAC processing (yellow) and transport (orange) or IDR value (blue/grey).
Cancer cell lines inevitably carry molecular alterations, and documenting them is essential to appropriately interpret the utility of these models. Thus, we also identified genes expressed at lower or higher levels in cell lines compared with primary samples. Genes at higher levels included signalling/inflammatory response genes, which may reflect changes associated with in vitro adaptation. Genes at lower levels were enriched for blood lineage and antigen binding, suggesting non-leukemic cells as a possible source. However, we also noted lower expression of drug-targetable receptor tyrosine kinases, including FLT1, FLT4, PDGFRB, ERBB2 and NTRK1 in two or more unrelated cell lines, suggesting the need to carefully select and validate models for growth factor-receptor tyrosine kinase perturbation studies. These results provide a catalogue of clinically relevant and conserved transcriptional features in vitro, and is the first report quantifying reproducibility of RNA-seq measurements in cell lines and matched primary material for any cancer type.
Our in vitro chemical screen identified consistent synergy between ROM and ARAC, the latter a key component of iALL therapy, where it is administered at high doses. In contrast, bortezomib had variable effects on ARAC and dexamethasone efficacy, although combinations of bortezomib and dexamethasone have been effective in other diseases such as multiple myeloma 40 and lightchain amyloidosis. 41 ROM also had variable effects on dexamethasone, suggesting that ROM or bortezomib may not be suitable for co-administration with dexamethasone in some iALL patients. Importantly, we found consistent synergistic enhancement of ARAC by three additional HDACis, supporting HDACs as therapeutic targets to potentiate ARAC killing, consistent with observations in pediatric acute myeloid leukemia cells. 42 The potentiation of ARAC by three HDACis is highly relevant given the current consideration to include HDACis in front-line treatment for iALL patients. Further studies are necessary to determine whether HDACis enhance ARAC in other malignancies treated with these agents such as acute myeloid leukemia. 43 Several studies indicate efficacy of drugs targeting chromatinassociated proteins in hematological malignancies. 44 By performing an unbiased screen of FDA-approved compounds, we confirmed in vitro sensitivity to a subset of HDACis. Sensitivity to HDACis, including ROM, has previously been reported against t(4,11) MLL-r iALL, 45 whereas sensitivity to HDAC-1/-2 genetic inhibition has also been shown in pediatric B-ALL. 46 We also recorded cytotoxic activity of additional agents targeting chromatin features, including three bromodomain and extra-terminal domain family inhibitors within the upper range of doses reported previously in MLL-r AML 47 and the histone H3K27-demethylase inhibitor, GSK-J4, in four cell lines, with an IC 50 dose range consistent with responses of T-ALL cells. 48 However, we did not detect growth inhibition activity of the EZH2 H3K27 methylase inhibitor GSK-343, consistent with findings that dual EZH1 and EZH2 inhibition is necessary for anti-leukemic effects in a murine model of MLL-r AML. 49 Taken together, our findings implicate the chromatin landscape as a therapeutic target in MLL-r iALL.
We observed variable efficacy of drugs currently used to treat iALL, with the exception of vincristine. Clofarabine and gemcitabine were more potent than currently used nucleoside analogues of the same respective class. These results emphasize the limitation of contemporary MLL-r iALL chemotherapeutics and indicate the potential of structurally related compounds as noted previously. 50 Importantly, not all of the novel drugs in the three identified classes (HDACis, proteasome inhibitors and cyclin-dependent kinase inhibitors) were efficacious, but those that were effective have demonstrable clinical activity against human hematological malignancies. 40, [51] [52] [53] [54] For example, dinaciclib in relapsed/refractory chronic lymphocytic leukemia 52 and relapsed multiple myeloma; 53 ROM in cutaneous and peripheral T-cell lymphoma; 54 and bortezomib for multiple myeloma 40 and mantle cell lymphoma. 51 The potential benefit of combining chromatin-modifying drugs with currently administered chemotherapeutic drugs is very attractive. Understanding their actions is fundamental to optimizing combination drug therapy. Our studies show that ROM potentiated the action of ARAC by affecting the cytidine-metabolizing pathway. Interestingly, the ARAC-deactivating enzyme, CDA was depleted after 2 h ROM treatment and fell below 20% within 8 h. We demonstrated that ROM also affects the DNA damage-response, and observed significantly increased γ-H2AX over and above the effect of ARAC alone. We noted distinct differences in response patterns in two iALL cell lines, which also differ by a factor of 16 in sensitivity to ARAC. Taken together, the drug effects are evident within hours under in vitro conditions and appear to be dependent on the features of each cell line. These observations are reflected by our xenograft studies, whereby the iALL cell line with a higher in vitro IC 50 (PER-826A) showed a poorer response to ARAC treatment in vivo, indicating that in vivo efficacy recapitulates in vitro sensitivity. Furthermore, the two xenograft models showed distinct responses to combined ROM-ARAC treatment. We demonstrated that the enhancing effect of ROM was evident when the drugs were administered 6 h apart, but diminished when administered 18 h apart. We conclude from in vitro and in vivo studies that the timing of drug administration is of critical importance, and warrants further optimization. Further studies are required integrating analyses of chromatin, transcription and protein expression in order to characterize the sequence of changes induced by this drug combination to modulate the DNA damageresponse and induce cytoxicity.
In conclusion, we have generated a novel panel of molecularly characterized MLL-r iALL cell lines. Our data using this panel of cell lines showed variable efficacy of several drugs currently used to treat iALL. We have identified several FDA-approved anti-cancer drugs showing cytotoxic effects in MLL-r iALL cells, which are not presently used to treat this aggressive cancer. Our results highlight the clinical potential of drugs targeting chromatin for iALL therapy, in particular the FDA-approved HDACis. Leukemia infiltration in bone marrow, spleen and peripheral blood in mice xenografted with PER-785A (red) or PER-826A (blue) from two independent experiments. Leukemia burden in (c) PER-785A and (d) PER-826A xenografted mice was measured after 3-week treatment with 1 mg/kg twice/week ROM; 100 mg/kg ARAC three times/week; ROM and ARAC combined; or saline (n = 5 for each group). ROM was given either 6 h (left panels 'Schedule 1') or 18 h (right panels 'Schedule 2') before ARAC. Mice were culled 4 days post last injection of drug, and bone marrow analyzed by flow cytometry with anti-human CD19-FITC antibody. Percentage of human leukemia cells and s.d. are plotted with P-values calculated by one-way ANOVA and Tukey's multiple comparison tests (*P o0.05, **Po 0.01, ***P o0.001, ****P o0.0001).
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